What is VectorBuilder?
VectorBuilder stands as a global leader in gene delivery technologies, offering a comprehensive suite of solutions for both research and clinical applications. Their expertise spans vector design, cloning, viral vector manufacturing, and therapeutic RNA development, serving a diverse clientele of biotech and pharmaceutical companies worldwide. The company's commitment to innovation and scalability supports thousands of laboratories in their gene delivery endeavors, bridging the gap from benchtop research to bedside applications. VectorBuilder's user-friendly platform and dedicated expert support have established it as a trusted partner in advancing molecular biology research.
How much funding has VectorBuilder raised?
VectorBuilder has raised a total of $56M across 1 funding round:
Series C
$56M
Series C (2022): $56M with participation from Legend Capital
Key Investors in VectorBuilder
Legend Capital
Legend Capital is a private equity fund manager with a focus on innovation and growth enterprises, managing significant capital and having a substantial investment history in China-related companies.
What's next for VectorBuilder?
The recent major strategic investment into VectorBuilder signals a strong confidence in its growth trajectory and market position. This capital infusion is expected to fuel further expansion of its service offerings, enhance its manufacturing capabilities, and accelerate the development of novel gene delivery solutions. As VectorBuilder continues to scale its operations, it is poised to play an even more critical role in enabling cutting-edge research and therapeutic development within the rapidly evolving biotechnology landscape.
See full VectorBuilder company page
